{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-25-000039","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.881858+00:00","generated_at":"2026-05-24T10:30:55.930998+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026","bullets":["Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.","Planning underway for potential global pivotal trial of IMM-1-104 in first-line pancreatic cancer.","Cash $36.1M at Dec 31, 2024; plus $13.7M from ATM in Jan 2025; runway into 2026.","Named Dr. Igor Matushansky as Chief Medical Officer to lead clinical programs.","Phase 1 pancreatic cancer patient on IMM-1-104 monotherapy for 13+ months with stable disease and 91% CA 19-9 reduction."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-25-000039","json":"https://secwatch.observer/filing/0001790340-25-000039.json","markdown":"https://secwatch.observer/filing/0001790340-25-000039.md","text":"https://secwatch.observer/filing/0001790340-25-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/0001790340-25-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/imrx-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:30:55.930998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}